

## Special Issue

# Genetically Engineered Mouse Models in Vaccine Development

### Message from the Guest Editors

Mice are the most common model for preclinical evaluation of vaccine safety and efficacy. However, there remain many challenges. Due to the strict host tropism, some pathogens do not naturally infect mice. Furthermore, the mouse immune system cannot reconstitute immune responses by humans. To overcome these problems, a number of recent studies have developed genetically engineered mice (GEM) to test vaccine security and immunogenicity. The use of GEMs has exponentially increased, including knockout mice lacking a murine restriction factor, transgenic mice expressing a viral entry factor, and humanized immune system mice with reduced graft-versus-host disease and functional human B and T cells. These GEMs allow a more physiological study of human-restricted pathogens and novel vaccines. In this Special Issue, we aim to introduce new GEM models and will discuss current progress and future perspectives related to these models in vaccinology. We look forward to receiving your contributions.

---

### Guest Editors

Dr. Deshan Ren

Model Animal Research Center, Nanjing University, Nanjing, China

Dr. Bingqian Qu

Department of Infectious Diseases, University of Heidelberg, Heidelberg, Germany

---

### Deadline for manuscript submissions

31 January 2027



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/251902](https://mdpi.com/si/251902)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).